Accordingly, GF109203X a PKC inhibitor, U0126 a MEK1 inhibitor and PKCα/β knockdown restore sensitivity to IM while PKCα or PKCβ overexpression in CML cells promotes protection against IM-induced cell death. This evidence concerns the gene PRRT2 and chronic myelogenous leukemia, BCR-ABL1 positive.